Ibrutinib

Name: Ibrutinib | 936563-96-1
Brand: US-CATO
SKU: S57C4X-1064_5_MG
Price: 19998.0 USD
Availability: InStock

Cat. No S57C4X-1064_5_MG

Vendor: US-CATO

Product Information

Product Name

Ibrutinib

Brand Name

US-CATO

Product Number

C4X-1064

CAS

936563-96-1

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

24821094

IUPAC Name

1-(3R)-3-4-amino-3-(4-phenoxyphenyl)pyrazolo3,4-dpyrimidin-1-ylpiperidin-1-ylprop-2-en-1-one

InChI Key

XYFPWWZEPKGCCK-GOSISDBHSA-N

SMILES

C=CC(=O)N1CCCC@H(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N

References Data Source From Pubchem

Correction: Emerging Therapeutics in Rheumatoid Arthritis

Publication Name: Current Rheumatology Reports

Publication Date: 2026-03-17

DOI: 10.1007/s11926-025-01209-5|10.1007/s11926-026-01215-1

Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity

Publication Name: Cancer immunology, immunotherapy : CII

Publication Date: 2026-03-02

DOI: 10.1007/s00262-026-04335-w

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study

Publication Name: Journal of Neuro-Oncology

Publication Date: 2026-03-02

DOI: 10.1007/s11060-026-05492-9

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer

Publication Name: International Journal of Clinical Oncology

Publication Date: 2026-02-28

DOI: 10.1007/s10147-026-02994-4

An Update on Treatments for Recurrent Primary Central Nervous System Lymphoma

Publication Name: Current Oncology Reports

Publication Date: 2026-02-27

DOI: 10.1007/s11912-026-01756-9

Ibrutinib

Product Information

General Information

References Data Source From Pubchem

Correction: Emerging Therapeutics in Rheumatoid Arthritis

Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer

An Update on Treatments for Recurrent Primary Central Nervous System Lymphoma

Ibrutinib

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

About Us

Popular Searches

Contact

#title#

Features
Availability:
Price
Options
Actions

Ibrutinib

Product Information

General Information

References Data Source From Pubchem

Correction: Emerging Therapeutics in Rheumatoid Arthritis

Dasatinib boosts γδ T cell expansion and memory phenotypes with enhanced antitumor immunity

Real-world comparison of BTK inhibitors and lenalidomide as first-line maintenance in primary CNS lymphoma: a multi-center retrospective study

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer

An Update on Treatments for Recurrent Primary Central Nervous System Lymphoma

Ibrutinib

Related Product

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

#title#

Login

Register